T14.SI - Tianjin Zhong Xin Pharmaceutical Group Corporation Limited

SES - SES Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

Currency in CNY. All numbers in thousands
Breakdown
ttm
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Total Revenue
6,847,293
6,358,622
5,689,242
6,178,822
7,080,552
Cost of Revenue
3,977,487
3,722,834
3,480,047
4,177,748
4,990,034
Gross Profit
2,869,806
2,635,789
2,209,195
2,001,073
2,090,518
Operating Expenses
Research Development
126,364
100,925
-
-
-
Selling General and Administrative
2,147,055
1,998,927
1,794,682
1,630,442
1,612,117
Total Operating Expenses
2,324,849
2,159,627
1,851,913
1,687,854
1,658,939
Operating Income or Loss
544,957
476,162
357,282
313,220
431,580
Interest Expense
12,881
11,382
9,541
16,628
32,675
Total Other Income/Expenses Net
-
-
-
-
-
Income Before Tax
723,039
640,629
531,001
465,523
537,171
Income Tax Expense
105,339
72,841
57,740
57,911
79,303
Income from Continuing Operations
617,700
567,788
473,261
407,612
457,868
Net Income
605,838
561,680
476,080
422,423
451,443
Net Income available to common shareholders
605,838
561,680
476,080
422,423
451,443
Reported EPS
Basic
-
0.73
0.62
0.55
0.60
Diluted
-
0.73
0.62
0.55
0.60
Weighted average shares outstanding
Basic
-
769,424
767,871
768,042
752,405
Diluted
-
769,424
767,871
768,042
752,405
EBITDA
-
728,159
613,336
550,636
640,065